PCSK9 Neutralization Rate / Evolocumab ELISA Assay (RPE)
The PCSK9 Neutralization Rate / Evolocumab ELISA Assay is For Research Use Only
Sensitivity: Evolocumab: 0.2 µg/mL; PCSK9: 40 ng/ml
Dynamic Range: Evolocumab: 0.2 – 24 µg/mL; PCSK9 in sample without Evolocumab: 40-800 ng/ml; PCSK9 in sample with Evolocumab: 40-350 ng/ml
Incubation Time: Min 16 hours, Max 22 hours
Sample Type: Serum
Sample Size: 60 µL
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has importance because it interferes with the lipoprotein in particular the lipoprotein particles (LDL) homeostasis. PCSK9 binds to the lipoprotein particles receptor (LDLR) which transports fat molecules within the extracellular fluid. After LDL binding to the LDL receptor the complex of LDLR/PCSK9/LDL gets degraded in the hepatocytes upon internalization. Importantly, if PCSK9 does not bind to the complex, the LDLR can return to the surface of the cell and can thereby continue to remove LDL-particles from the bloodstream.
Agents which block PCSK9 can lower LDL particle concentrations in the blood. The therapeutically monoclonal antibody against PCSK9 Evolocumab, was approved by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.
To monitor the antibody (Evolocumab) concentration and the degree of neutralization of PCSK9 during Evolocumab therapy is beneficial to identify the ideal drug does for each patient individually. The PCSK9 Neutralization Rate / Evolocumab ELISA Assay Kit (RPE) allows the simultaneously determination of the free PCSK9 and the free Evolocumab in one ELISA assay.